JP6208749B2 - 薬剤溶出性で磁気共鳴画像法で検出可能な血管閉塞用インプラントとしての使用に適した生体材料 - Google Patents

薬剤溶出性で磁気共鳴画像法で検出可能な血管閉塞用インプラントとしての使用に適した生体材料 Download PDF

Info

Publication number
JP6208749B2
JP6208749B2 JP2015514174A JP2015514174A JP6208749B2 JP 6208749 B2 JP6208749 B2 JP 6208749B2 JP 2015514174 A JP2015514174 A JP 2015514174A JP 2015514174 A JP2015514174 A JP 2015514174A JP 6208749 B2 JP6208749 B2 JP 6208749B2
Authority
JP
Japan
Prior art keywords
acrylamide
iron oxide
biomaterial
microspheres
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015514174A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015517390A5 (enExample
JP2015517390A (ja
Inventor
レブ，フィリッペ
シェクス，セリーヌ
トーマス，メリアデグ
Original Assignee
バイオスフィア メディカル，インコーポレイテッド
バイオスフィア メディカル，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオスフィア メディカル，インコーポレイテッド, バイオスフィア メディカル，インコーポレイテッド filed Critical バイオスフィア メディカル，インコーポレイテッド
Publication of JP2015517390A publication Critical patent/JP2015517390A/ja
Publication of JP2015517390A5 publication Critical patent/JP2015517390A5/ja
Application granted granted Critical
Publication of JP6208749B2 publication Critical patent/JP6208749B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1854—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly(meth)acrylate, polyacrylamide, polyvinylpyrrolidone, polyvinylalcohol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
JP2015514174A 2012-05-24 2013-05-23 薬剤溶出性で磁気共鳴画像法で検出可能な血管閉塞用インプラントとしての使用に適した生体材料 Active JP6208749B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261651389P 2012-05-24 2012-05-24
US61/651,389 2012-05-24
PCT/US2013/042363 WO2013177364A1 (en) 2012-05-24 2013-05-23 Biomaterials suitable for use as drug eluting, magnetic resonance imaging detectable implants for vascular occlusion

Publications (3)

Publication Number Publication Date
JP2015517390A JP2015517390A (ja) 2015-06-22
JP2015517390A5 JP2015517390A5 (enExample) 2015-10-29
JP6208749B2 true JP6208749B2 (ja) 2017-10-04

Family

ID=49621771

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015514174A Active JP6208749B2 (ja) 2012-05-24 2013-05-23 薬剤溶出性で磁気共鳴画像法で検出可能な血管閉塞用インプラントとしての使用に適した生体材料

Country Status (7)

Country Link
US (1) US10695440B2 (enExample)
EP (2) EP3295961B1 (enExample)
JP (1) JP6208749B2 (enExample)
BR (1) BR112014029149A2 (enExample)
CA (1) CA2866896C (enExample)
ES (1) ES2655656T3 (enExample)
WO (1) WO2013177364A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3295961B1 (en) 2012-05-24 2020-04-08 Biosphere Medical Inc. Biomaterials suitable for use as drug eluting, magnetic resonance imaging detectable implants for vascular occlusion
JP6405369B2 (ja) 2013-09-19 2018-10-17 テルモ株式会社 ポリマー粒子
JP6641265B2 (ja) 2013-09-19 2020-02-05 マイクロベンション インコーポレイテッドＭｉｃｒｏｖｅｎｔｉｏｎ， Ｉｎｃ． ポリマーフィルム
CN105916495B (zh) 2013-11-08 2019-11-12 泰尔茂株式会社 聚合物颗粒
US9907880B2 (en) 2015-03-26 2018-03-06 Microvention, Inc. Particles
KR102566112B1 (ko) 2016-09-28 2023-08-10 테루모 가부시키가이샤 중합체 입자

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS509858A (enExample) 1973-06-02 1975-01-31
JPS6056676B2 (ja) 1980-07-18 1985-12-11 日立造船株式会社 コンクリ−ト複合パネル
ATE130517T1 (de) 1990-08-08 1995-12-15 Takeda Chemical Industries Ltd Intravaskulär embolisierendes mittel mit gehalt an einem die angiogenesis hemmenden stoff.
FR2676927B1 (fr) * 1991-05-29 1995-06-23 Ibf Microspheres utilisables pour les occlusions vasculaires therapeutiques et solutions injectables les contenant.
US5514379A (en) 1992-08-07 1996-05-07 The General Hospital Corporation Hydrogel compositions and methods of use
US6315709B1 (en) 1998-08-07 2001-11-13 Stereotaxis, Inc. Magnetic vascular defect treatment system
CN101708165A (zh) * 2000-03-24 2010-05-19 生物领域医疗公司 用于主动栓塞术的微球体
FR2808026B1 (fr) 2000-04-25 2002-06-14 Alexandre Laurent Biomateriau a base de polymere hydrophile presentant un signal specifique en imagerie par resonance magnetique et procede de preparation d'un tel biomateriau
JP2005053707A (ja) 2001-07-30 2005-03-03 Kankyo Device Kenkyusho:Kk 可視光応答性材料の製造方法
US7462366B2 (en) * 2002-03-29 2008-12-09 Boston Scientific Scimed, Inc. Drug delivery particle
US8012454B2 (en) 2002-08-30 2011-09-06 Boston Scientific Scimed, Inc. Embolization
US20040161466A1 (en) * 2003-02-14 2004-08-19 Biocompatibles Uk Limited Chemoembolisation
JP4909071B2 (ja) 2003-03-24 2012-04-04 プルーローメッド， インコーポレイテッド 逆感熱性ポリマーを使用する一時的な塞栓形成
US20050058603A1 (en) * 2003-05-02 2005-03-17 Case Western Reserve University Drug delivery system based on polymer nanoshells
EP2143740B1 (en) * 2004-08-19 2013-06-19 Covidien LP Water-swellable copolymers and articles and coating made therefrom
US20110104052A1 (en) * 2007-12-03 2011-05-05 The Johns Hopkins University Methods of synthesis and use of chemospheres
GB0807154D0 (en) * 2008-04-18 2008-05-21 Univ Aston Intervertebral disc
JP5792714B2 (ja) * 2009-05-28 2015-10-14 コーニング インコーポレイテッド 細胞培養のための膨潤性の合成マイクロキャリア
EP2451488A2 (en) 2009-07-07 2012-05-16 Bartling, Sönke Multimodal visible polymer embolization material
EP3295961B1 (en) 2012-05-24 2020-04-08 Biosphere Medical Inc. Biomaterials suitable for use as drug eluting, magnetic resonance imaging detectable implants for vascular occlusion

Also Published As

Publication number Publication date
US20130315838A1 (en) 2013-11-28
ES2655656T3 (es) 2018-02-21
US10695440B2 (en) 2020-06-30
EP3295961A1 (en) 2018-03-21
CA2866896C (en) 2021-01-26
EP2854869B1 (en) 2017-11-01
WO2013177364A1 (en) 2013-11-28
JP2015517390A (ja) 2015-06-22
BR112014029149A2 (pt) 2017-06-27
EP2854869A4 (en) 2015-12-30
CA2866896A1 (en) 2013-11-28
EP2854869A1 (en) 2015-04-08
EP3295961B1 (en) 2020-04-08

Similar Documents

Publication Publication Date Title
US11998563B2 (en) Polymeric treatment compositions
JP6208749B2 (ja) 薬剤溶出性で磁気共鳴画像法で検出可能な血管閉塞用インプラントとしての使用に適した生体材料
KR101297500B1 (ko) 치료적 혈관 색전술에 유용한 마이크로스피어
BR112015008245B1 (pt) Composições poliméricas de tratamento
US12390530B2 (en) Stimuli responsive block copolymers
JP2025108532A (ja) 非分解性の塞栓ミクロスフェア
KR20220079600A (ko) 비분해성 방사선 불투과성 색전술 미소구체
Lewis Embolisation devices from biomedical polymers for intra-arterial occlusion and drug delivery in the treatment of cancer
Jensen et al. 03: 18 PM Abstract No. 385 Radiopaque silk-elastinlike protein polymer-based embolic
WO2024206400A1 (en) Liquid embolic materials

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150901

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170405

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20170621

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170724

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170815

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170907

R150 Certificate of patent or registration of utility model

Ref document number: 6208749

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250